TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27687648

Group type: EXPERIMENTAL
Intervention: Yunnan Baiyao (YNBY)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY in E1 subgroup
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control in E1 subgroup
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY in E2 subgroup
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control in E2 subgroup
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY in E3 subgroup
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control in E3 subgroup
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY in mild cases
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control in mild cases
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY in moderate cases
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control in moderate cases
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY in severe cases
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control in severe cases
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY with mesalazine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control with mesalazine
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY with corticosteroid
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control with corticosteroid
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: YNBY with infliximab
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control with infliximab
Number of subjects: 221
Study: 25479207

Group type: EXPERIMENTAL
Intervention: Coblation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Microdebrider
Number of subjects: 70
Study: 23538338

Group type: EXPERIMENTAL
Intervention: Low-dose cytarabine plus daunorubicin and etoposide
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine plus daunorubicin and etoposide
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: rs1203633 AA genotype
Number of subjects: 523
Study: 20659966

Group type: EXPERIMENTAL
Intervention: Closed reduction and intramedullary splinting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conservative treatment without reduction
Number of subjects: 40
Study: 17590313

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) activity, 2-3 times weekly for 12 weeks using GestureTek's Gesture Xtreme video capture VR system
Number of subjects: 33
Study: 16836708

Group type: EXPERIMENTAL
Intervention: Cocaine (20 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12791613

Group type: EXPERIMENTAL
Intervention: High-almond diet (20% of energy from almonds)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Step I diet
Number of subjects: 25
Study: 10912656

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no PPIs)
Number of subjects: 46
Study: 8700955

Group type: EXPERIMENTAL
Intervention: Auditory stimulus condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimulus condition
Number of subjects: 0
Study: 1588392

Group type: EXPERIMENTAL
Intervention: Varying speed of arm movements with different movement times, including static trials where the arm was held still.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static trials where the subject held the arm still at various postures (initial, final, halfway).
Number of subjects: 0
Study: 31593637

Group type: COMPARATOR
Intervention: Placebo of vitamin D3 (n = 23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement at a dose of 50,000 IU/week (n = 23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: CrPic supplement at a dose of 500 μg/day (n = 23)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both vitamin D3 at a dose of 50,000 IU/week and CrPic at a dose of 500 μg/day (n = 23)
Number of subjects: 92
Study: 29747625

Group type: EXPERIMENTAL
Intervention: Leaflet cluster (oral health education through leaflets)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Leaflet cluster
Number of subjects: 220

Group type: COMPARATOR
Intervention: E-learning cluster (oral health education through E-learning program)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both clusters
Number of subjects: 220
Study: 27025586

Group type: COMPARATOR
Intervention: Endocrine Treatment (ET) alone
Number of subjects: 875

Group type: EXPERIMENTAL
Intervention: Endocrine Treatment (ET) + Radiotherapy (RAD)
Number of subjects: 875
Study: 25036199

Group type: EXPERIMENTAL
Intervention: Dural suturing with TachoSil
Number of subjects: 229

Group type: COMPARATOR
Intervention: Dural suturing alone (Control)
Number of subjects: 229
Study: 22418829

Group type: EXPERIMENTAL
Intervention: ACT‐077825 (1-1,000 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Enalapril 20 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 20329580

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 18715218

Group type: COMPARATOR
Intervention: 1,000 mg of CrPic for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intraperitoneal administration of CrPic (0, 1, 10, or 50 microg/kg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intracerebroventricular administration of CrPic (0, 0.4, 4, or 40 ng)
Number of subjects: 42
Study: 16439811

Group type: EXPERIMENTAL
Intervention: Petrolatum-based ointments
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-alcohol barrier film
Number of subjects: 16
Study: 12859474

Group type: EXPERIMENTAL
Intervention: Curved bougie
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coudé-tipped bougie
Number of subjects: 30

Group type: COMPARATOR
Intervention: Straight bougie
Number of subjects: 30

Group type: COMPARATOR
Intervention: Straight straight-tipped bougie
Number of subjects: 30
Study: 10376614

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 12.5 mg (NYHA III‐IV) or 25.0 mg once daily (NYHA II), target dose 200 mg once daily, up-titrated over 8 weeks
Number of subjects: 3991

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study: 8708804

Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Ayre spatula plus Cytobrush
Number of subjects: 252

Group type: COMPARATOR
Intervention: Ayre spatula plus cotton swab
Number of subjects: 252
Study: 1809418

Group type: EXPERIMENTAL
Intervention: High frequency nonpainful TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 6401193

Group type: EXPERIMENTAL
Intervention: 1-deamino-8-D-arginine vasopressin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30882963

Group type: EXPERIMENTAL
Intervention: Wide-field enhanced-depth imaging optical coherence tomography
Number of subjects: 27
Study: 29211888

Group type: EXPERIMENTAL
Intervention: OCP + BC (50 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: OCP + P
Number of subjects: 70
Study: 26725050

Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft (n = 31)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Semitendinosus tendon autograft (n = 31)
Number of subjects: 62
Study: 24469526

Group type: EXPERIMENTAL
Intervention: Psychodynamic psychotherapy plus adjunctive pharmacotherapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Multimodal psychodynamic psychotherapy only
Number of subjects: 33
Study: 22698700

Group type: EXPERIMENTAL
Intervention: 400 μg of misoprostol
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 19857859

Group type: EXPERIMENTAL
Intervention: Interpretation modification condition (benign interpretive bias)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (accessing threat and benign meanings with equal frequency)
Number of subjects: 0
Study: 16943401

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg daily
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1561
Study: 14502372

Group type: EXPERIMENTAL
Intervention: Erythromycin estolate, 20 mg kg‐1 day‐1, divided into four oral doses for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 14
Study: 10732392

Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (SPE) 160 mg standardized extract twice daily
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Saw palmetto extract (SPE)
Number of subjects: 1
Study: 8909345

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 210
Study: 1327632

Group type: EXPERIMENTAL
Intervention: Liquorice (7 days of oral administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congenital 11 beta‐hydroxysteroid dehydrogenase deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol (intra-arterial infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 0
Study: 3901992

Group type: EXPERIMENTAL
Intervention: Cephamandole (1 g single dose given 1 hour before surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (given 1 hour before surgery)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cephamandole (1 g single dose)
Number of subjects: 200
Study: 31987548

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 30481690

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 77

Group type: COMPARATOR
Intervention: N-back task (control task)
Number of subjects: 77
Study: 29318159

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 310
Study: 25760565

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 97

Group type: COMPARATOR
Intervention: d4T or ZDV (Control)
Number of subjects: 97
Study: 23350632

Group type: EXPERIMENTAL
Intervention: Lodenafil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 20493567

Group type: EXPERIMENTAL
Intervention: Captopril or Losartan (not specified dosage or duration)
Number of subjects: 233
Study: 19186906

Group type: EXPERIMENTAL
Intervention: Behavioral mirroring by a confederate
Number of subjects: 2

Group type: COMPARATOR
Intervention: No behavioral mirroring by a confederate
Number of subjects: 2
Study: 16719233

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 to 8 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glibenclamide (3.5 to 10.5 mg daily)
Number of subjects: 20
Study: 15458525

Group type: EXPERIMENTAL
Intervention: 595‐nm pulsed dye laser + 1450‐nm diode laser (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 595‐nm pulsed dye laser (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1450‐nm diode laser (Group C)
Number of subjects: 30
Study: 11413528

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (various protocols including intraarterial and intravenous epirubicin, oral tegafur, carmofur)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Resection alone
Number of subjects: 108
Study: 9688399

Group type: EXPERIMENTAL
Intervention: Co-culture with Vero cells
Number of subjects: 11
Study: 8185465

Group type: EXPERIMENTAL
Intervention: Stroke rehabilitation services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Varying levels of rehabilitation services
Number of subjects: 0
Study: 2817770

Group type: EXPERIMENTAL
Intervention: Diet rich in starch (300 grams)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diet low in starch (100 grams)
Number of subjects: 6
Study: 802975

Group type: EXPERIMENTAL
Intervention: Anesthetic (sensory deprivation of the oral cavity via nerve-block injections)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (insertions of a hypodermic needle without anesthetic)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6
Study: 31311067

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus
Number of subjects: 7240

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus (adjusted)
Number of subjects: 7240

Group type: EXPERIMENTAL
Intervention: Age ≥45 years (adjusted)
Number of subjects: 7240

Group type: COMPARATOR
Intervention: Non-systemic lupus erythematosus (control)
Number of subjects: 7240
Study: 29095376

Group type: EXPERIMENTAL
Intervention: Triacylglycerol 50:2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phosphoglyceride 34:2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plasmenyl phosphocholine 38:1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phosphatidic acid 28:1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Four statistically significant lipids
Number of subjects: 30
Study: 25179493

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Adefovir dipivoxil
Number of subjects: 189
Study: 23112341

Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed circumcision (control)
Number of subjects: 0
Study: 21467538

Group type: EXPERIMENTAL
Intervention: Visionary leaders (those who offer novel solutions)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Representative leaders
Number of subjects: 5
Study: 18342989

Group type: EXPERIMENTAL
Intervention: Temptation group instructed to abstain from a favourite snack for 24h while being exposed to it.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group with no specific instructions.
Number of subjects: 68
Study: 16575425

Group type: EXPERIMENTAL
Intervention: slow rTMS over the left OFC
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo treatment over the left OFC
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: rTMS over the left dorsolateral portion of the prefrontal cortex
Number of subjects: 12
Study: 12752077

Group type: EXPERIMENTAL
Intervention: Midwife performed ET
Number of subjects: 102

Group type: COMPARATOR
Intervention: Gynecologist performed ET
Number of subjects: 102
Study: 11493164

Group type: EXPERIMENTAL
Intervention: Alzheimer disease without stroke (possible and probable)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Dementia with cerebrovascular disease
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Patients aged 80 years and older with dementia with cerebrovascular disease
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Patients younger than 80 years with dementia with cerebrovascular disease
Number of subjects: 339
Study: 9249774

Group type: EXPERIMENTAL
Intervention: Citrate anticoagulation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heparin anticoagulation
Number of subjects: 10
Study: 8126317

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.6 mg/kg)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Methylphenidate first followed by placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Placebo first followed by methylphenidate
Number of subjects: 288
Study: 2965135

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vancomycin 1 g bd
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 21
Study: 29316570

Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) group
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Shortened dental arch (SDA) group
Number of subjects: 152

Group type: COMPARATOR
Intervention: Age (covariate)
Number of subjects: 152

Group type: COMPARATOR
Intervention: DMFT value (covariate)
Number of subjects: 152
Study: 27898460

Group type: EXPERIMENTAL
Intervention: Smartphone pain app with 2-way messaging, N=52
Number of subjects: 105

Group type: COMPARATOR
Intervention: Smartphone pain app without 2-way messaging
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Both groups using the smartphone pain app
Number of subjects: 105
Study: 24815417

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.5 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Diclofenac 2.0 mg·kg(‐1) with acetaminophen 40 mg·kg(‐1) before surgery and 20 mg·kg(‐1) rectally at the end of surgery
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1 mg·kg(‐1) only
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.5 mg·kg(‐1) only
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Diclofenac 2.0 mg·kg(‐1) only
Number of subjects: 151

Group type: COMPARATOR
Intervention: Acetaminophen 30 mg·kg(‐1)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 22791166

Group type: EXPERIMENTAL
Intervention: Elcatonin (ECT) 20 units intramuscularly per week
Number of subjects: 61

Group type: COMPARATOR
Intervention: Risedronate (17.5 mg weekly)
Number of subjects: 61
Study: 20124282

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled i.v. opiate analgesia (PCA)
Number of subjects: 60
Study: 17586782

Group type: EXPERIMENTAL
Intervention: Sertraline 50-100 mg/day
Number of subjects: 747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 747
Study: 16128676

Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Lactobacillus rhamnosus GG, L. rhamnosus LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp. shermanii JS, taken daily for 6 months.
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo capsule taken daily for 6 months.
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 103
Study: 12450692

Group type: EXPERIMENTAL
Intervention: COMVAX plus placebo
Number of subjects: 1215

Group type: COMPARATOR
Intervention: PedvaxHIB plus RECOMBIVAX HB
Number of subjects: 1215
Study: 10086942

Group type: EXPERIMENTAL
Intervention: Ventstream nebuliser (MMD, 3.3 microm; delivery rate, 0.075 ml/min)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Optimist nebuliser (MMD, 1.8 microm; delivery rate, 0.02 ml/min)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Comparison of both nebulisers in 20 patients
Number of subjects: 33
Study: 7822046

Group type: EXPERIMENTAL
Intervention: Live oral cholera vaccine CVD 103-HgR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2239116

Group type: EXPERIMENTAL
Intervention: 10 mg 0.5% bupivacaine after free drops of CSF (Group I)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 10 mg 0.5% bupivacaine after removal of 3 ml CSF (Group II)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 10 mg 0.5% bupivacaine after removal of 5 ml CSF (Group III)
Number of subjects: 66
Study: 497087

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide administration
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide administration
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both intravenous and oral cyclophosphamide administration
Number of subjects: 7
Study: 31918431

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 34
Study: 29952697

Group type: EXPERIMENTAL
Intervention: ReBound diathermy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Moist hot packs
Number of subjects: 3

Group type: COMPARATOR
Intervention: MegaPulse II pulsed shortwave diathermy
Number of subjects: 3
Study: 25036048

Group type: EXPERIMENTAL
Intervention: Hepavax-Gene thiomersal-containing (TC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hepavax-Gene thiomersal-free (TF)
Number of subjects: 0
Study: 23378064

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulvestrant 250 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of Fulvestrant 500 mg to Fulvestrant 250 mg
Number of subjects: 0
Study: 21098066

Group type: EXPERIMENTAL
Intervention: Exercise training (six-month trainer-supervised program)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control treatment (education session with monthly phone follow-ups)
Number of subjects: 39
Study: 20183536

Group type: EXPERIMENTAL
Intervention: Videobike gaming
Number of subjects: 29

Group type: COMPARATOR
Intervention: Self-selected music cycling (comparison condition)
Number of subjects: 29
Study: 17684085

Group type: EXPERIMENTAL
Intervention: End-range mobilization (ERM)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Mid-range mobilization (MRM)
Number of subjects: 28
Study: 16724337

Group type: EXPERIMENTAL
Intervention: Initial portal revascularization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Initial arterial revascularization
Number of subjects: 60
Study: 12599046

Group type: EXPERIMENTAL
Intervention: Breast-milk ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast-feeding per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced maternal disease (measured by prenatal HIV-1 RNA plasma levels and CD4 cell counts)
Number of subjects: 0
Study: 10451073

Group type: EXPERIMENTAL
Intervention: Psoriasis affected body surface area (BSA)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Severity of psoriasis
Number of subjects: 221

Group type: COMPARATOR
Intervention: Comparison of BSA by ethnicity
Number of subjects: 221

Group type: COMPARATOR
Intervention: Target lesion severity by ethnicity
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Psoriatic nail disease and DIP joint involvement
Number of subjects: 221
Study: 8633914

Group type: EXPERIMENTAL
Intervention: New hub model
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard connectors (control group)
Number of subjects: 151
Study: 1767056

Group type: EXPERIMENTAL
Intervention: Iopamidol 150 mgI/ml (250 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iopamidol 370 mgI/ml (100 ml)
Number of subjects: 60